So far, BSX stock has risen 19% year-to-date. Separately, CROX reports earnings tomorrow. Will the stock pop on the news? See ...

Jeffrey B. Mirviss, Executive Vice President and President of Peripheral Interventions at Boston Scientific Corp (NYSE:BSX), ...

Bloomberg Law reported earlier this week that Medtronic and Axonics — now part of Boston Scientific — settled their ...

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

Stifel analysts increased their price target on Boston Scientific Corporation (NYSE:BSX) shares from $115.00 to $120.00, while reiterating a Buy rating for the medical device company. The adjustment ...

But there’s a powerful fundamental story happening with Boston Scientific. Also, EPS is estimated to ramp higher this year by +13.8%. Now it makes sense why the stock has been powering to new ...

Feb 5 (Reuters) - Medical device maker Boston Scientific (BSX.N), opens new tab forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.

I’m still a believer in the story at Boston Scientific, but the valuation situation remains challenging. I do think there’s a credible chance of BSX generating 10% long-term revenue growth and ...

Commanding a market cap of $150.9 billion, Boston Scientific Corporation (BSX) is a global medical device manufacturer that develops, manufactures, and markets a broad range of innovative products.

Boston Scientific’s BSX robust expansion of operations across different geographies outside the United States is poised to help it grow in the upcoming quarters. The company’s ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Boston Scientific (BSX – Research Report), with a price target ...